Signaturefd LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,754 shares of the company’s stock after purchasing an additional 6,372 shares during the quarter. Johnson & Johnson makes up approximately 0.7% of Signaturefd LLC’s investment portfolio, making the stock its 18th largest position. Signaturefd LLC’s holdings in Johnson & Johnson were worth $4,453,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the period. Taylor Wealth Management Partners grew its holdings in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares during the period. Foundation Resource Management Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $204,000. Finally, Arbor Investment Advisors LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $215,000. Hedge funds and other institutional investors own 66.00% of the company’s stock.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
JNJ has been the subject of a number of research analyst reports. BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a report on Sunday, May 21st. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a report on Monday, May 29th. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Johnson & Johnson in a report on Friday, June 2nd. Cowen and Company reiterated an “outperform” rating and set a $143.00 price target on shares of Johnson & Johnson in a report on Tuesday, June 13th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $134.60.
Johnson & Johnson (NYSE:JNJ) traded up 0.20% during midday trading on Friday, reaching $134.45. The company’s stock had a trading volume of 15,522,011 shares. The company has a 50 day moving average of $132.62 and a 200-day moving average of $129.18. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company has a market capitalization of $360.86 billion, a P/E ratio of 22.75 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
WARNING: This report was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.truebluetribune.com/2017/09/17/johnson-johnson-jnj-holdings-lifted-by-signaturefd-llc.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.